Seller record · Telehealth service

Premium Health

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S4, compounding disclosure: The weight loss pages sell compounded semaglutide and tirzepatide, and no page, including the answers and the privacy notice, states that compounded medications are not FDA-approved; the side-effects answer points to the brand drug's FDA label instead. 2 more criteria also fail; see the table below.

At a glance

Premium HealthTelehealth service

5/8criteria passed
Price
Semaglutide $275 a month, tirzepatide $445, medication included
Sells
compounded semaglutide with B12 or B6, compounded tirzepatide, and 2 more
FDA letters
1 on file
Visit Premium HealthSee all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A California telehealth and in-home IV therapy company selling compounded semaglutide and tirzepatide on all-inclusive monthly memberships after a video visit, along with NAD+ and other IV drips given at home by a nurse. It names three filling pharmacies, and a February 2026 FDA warning letter names its operating company.

Operating entity Premium Health Management, Inc.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSPremium Health's weight loss page; Premium Health's semaglutide page
S2Prescription gatingPASSPremium Health's weight loss page; Premium Health's tirzepatide page
S3Pharmacy identificationPASSPremium Health's weight loss page; Premium Health's tirzepatide page
S4Compounding disclosureFAILPremium Health's weight loss page; Premium Health's semaglutide page; Premium Health's privacy notice
S5Analytical documentationFAILPremium Health's weight loss page; Premium Health's privacy notice
S6Business addressFAILPremium Health's contact page; Premium Health's privacy notice; Premium Health's consumer health data policy
S7Price disclosurePASSPremium Health's weight loss page; Premium Health's NAD+ plus page
S8Enforcement statusPASSFDA's website; FDA warning letter 721474

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSLicensed clinicians trained in obesity medicine hold a two-way video visit with each patient after the medical intake forms, and the prescription is filled only upon medical approval.Source: Premium Health's weight loss page; Premium Health's semaglutide page.
S2PASSThe steps begin with an online form covering health history and weight loss goals and a video visit with a licensed clinician, and the answers say sign-up starts with that form to see whether the buyer is a good fit, with the prescription filled only upon medical approval.Source: Premium Health's weight loss page; Premium Health's tirzepatide page.
S3PASSThe answers name the licensed pharmacy partners that prepare the semaglutide and tirzepatide: Hallandale Pharmacy, Red Rock Pharmacy and Strive Pharmacy.Source: Premium Health's weight loss page; Premium Health's tirzepatide page.
S4FAILThe weight loss pages sell compounded semaglutide and tirzepatide, and no page, including the answers and the privacy notice, states that compounded medications are not FDA-approved; the side-effects answer points to the brand drug's FDA label instead.Source: Premium Health's weight loss page; Premium Health's semaglutide page; Premium Health's privacy notice.
S5FAILNo certificate of analysis or lot document is published on the weight loss pages, the answers, the privacy notice or the consumer health data policy.Source: Premium Health's weight loss page; Premium Health's privacy notice.
S6FAILThe seller prints two different addresses. The contact page gives 220 Technology Dr, Ste. 215, Irvine, CA 92618, while the privacy notice and the consumer health data policy name Premium Health Management Inc. at 1800 E. Garry Ave., Suite 224, Santa Ana, CA 92705.Source: Premium Health's contact page; Premium Health's privacy notice; Premium Health's consumer health data policy.
S7PASSCompounded semaglutide at $275 a month and compounded tirzepatide at $445 a month, each including the medication, supplies and shipping, month to month with no long-term contract. A higher dose costs $100 a month more for semaglutide and $150 more for tirzepatide, and the in-home NAD+ IV drip costs $449.Source: Premium Health's weight loss page; Premium Health's NAD+ plus page.
S8PASSFDA warning letter 721474, February 2026, names Premium Health Management Inc. dba Premium Health at the Santa Ana, California address the privacy notice prints, alleging that pictured labels presented Premium Health as the compounder of its semaglutide and tirzepatide and that claims such as generic compounded medication and the active ingredient used in the brand drugs implied FDA approval. No close-out letter appears in the index. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 721474.

Products shown on the seller's own pages at the recorded date: compounded semaglutide with B12 or B6, compounded tirzepatide, NAD+ IV therapy, IV hydration therapy.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatideWho sells NAD+

Enforcement documents on file: 1 warning letter

FDA warning letter 721474, issued February 2026, to Premium Health Management Inc. dba Premium HealthPictured labels identify Premium Health as the compounder of semaglutide and tirzepatide products when it is not, and claims of equivalence to the brand drugs, such as generic compounded medication and the active ingredient used in Ozempic and Wegovy, imply the compounded products have been FDA-approved when they have not.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Premium Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.